<DOC>
	<DOCNO>NCT00003435</DOCNO>
	<brief_summary>RATIONALE : Antiviral agent drug act virus may effective treatment HIV . Peripheral stem cell transplantation umbilical cord blood transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . Combining either umbilical cord blood transplantation peripheral stem cell transplantation antiviral therapy may effective treatment HIV-positive patient hematologic cancer . PURPOSE : Phase I trial study effectiveness antiviral therapy plus either peripheral stem cell transplantation umbilical cord blood transplantation treat HIV-positive patient refractory recurrent hematologic cancer .</brief_summary>
	<brief_title>Antiviral Therapy Plus Either Peripheral Stem Cell Umbilical Cord Blood Transplantation Treating Patients Who Are HIV Positive Have Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility safety combination antiretroviral therapy follow HLA match sibling peripheral blood stem cell unrelated umbilical cord blood transplant HIV infect adult hematologic malignancy . II . Measure effect treatment HIV viral burden serum tissue patient . III . Measure immune reconstitution follow treatment patient population . OUTLINE : Patients receive combination 3 antiretroviral agent begin least 3 week prior initiation myeloablative conditioning regimen . The antiretroviral agent discontinue day -5 -1 prior transplant . Beginning day 0 antiretroviral agent restart continue indefinitely . Patients give umbilical cord blood ( UCB ) transplant undergo collection autologous peripheral blood stem cell ( PBSC ) prior myeloablative condition regimen case UCB graft failure . Prior PBSC UCB transplantation day 0 , patient receive myeloablative conditioning regimen . The condition regimen consist total body irradiation twice day day -9 -5 melphalan IV 60 minute day -4 -2 . Patients receive UCB transplant also receive anti-thymocyte globulin 6 hour day -3 -1 . Patients follow every 3 month 3 year , annually next 3 year . PROJECTED ACCRUAL : A total 6 patient accrue study 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate high grade nonHodgkin 's lymphoma , acute myelogenous leukemia , acute lymphocytic leukemia refractory relapse prior therapy Must HIV seropositive confirm Western blot Must 6/6 HLA match sibling donor 6/6 , 5/6 , 4/6 HLA match umbilical cord blood ( UCB ) New York Blood Center 's Unrelated UCB Bank homozygous CCR5 mutation No active primary CNS lymphoma chronic CNS infection No history AIDS defining opportunistic infection active invasive aspergillus infection A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 55 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month ( unless due hematologic malignancy ) Hematopoietic : Peripheral CD4 count great 100/mm3 Hepatic : Transaminases great 4 time normal Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No myocardial infarction within past 6 month Normal cardiac function ( LVEF great 40 % ) Pulmonary : FVC FEV1 great 70 % predict DLCO least 60 % predict Other : No malignancy except nonmelanoma skin cancer carcinoma situ cervix within past 5 year Not pregnant ( must negative pregnancy test within 2 week therapy ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow , peripheral blood stem cell , umbilical cord blood transplant Chemotherapy : Cumulative lifetime dose doxorubicin great 450 mg/m2 ( equivalent dose mitoxantrone daunorubicin ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent involvement clinical trial may affect hematologic engraftment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
</DOC>